Drug Discovery

nference enters into R&D data science partnership with Janssen

nference, a leader in knowledge synthesis software solutions for the life sciences industry, today announced a multi-year alliance with Janssen Research & Development, LLC that will leverage the nference artificial intelligence (AI) platform to create a unified data science-powered connective fabric across the Janssen R&D organization.

Vertex Pharmaceuticals to buy US firm Exonics Therapeutics

Vertex Pharmaceuticals has signed an agreement to acquire US-based Exonics Therapeutics in a deal valued up to $1bn (£787m).

Lantheus, NanoMab to offer novel biomarker to develop immuno-oncology therapies

Lantheus Holdings has collaborated with NanoMab Technology to provide a novel biomarker for clinical development and management of immuno-oncology therapies.

Boehringer Ingelheim, Gubra to develop anti-obesity peptide poly-agonists

Boehringer Ingelheim and Gubra announce a second collaboration and license agreement for the development of novel poly-agonist peptides to treat obesity.

Juvenescence launches Souvien Therapeutics to address neurodegenerative diseases

Juvenescence, a life sciences company developing therapeutics and technologies to treat diseases of aging and increase human longevity, is pleased to announce its latest biotech company Souvien Therapeutics (“Souvien”), creating innovative medicines to address neurodegenerative diseases by targeting the epigenetic underpinnings of neurodegeneration.

Viela Bio collaborates with Hansoh Pharma to develop and commercialize inebilizumab for autoimmune diseases and hematologic cancers in China

Viela Bio and Hansoh Pharmaceutical Group announced a collaboration focused on development and commercialization of inebilizumab – Viela’s humanized anti-CD19 monoclonal antibody – in China for neuromyelitis optica spectrum disorder (NMOSD), as well as other potential inflammation/autoimmune and hematologic malignancy indications.

Lilly to buy rights to Centrexion’s non-opoid pain asset CNTX-0290

Eli Lilly and Company (Lilly) has agreed to buy the exclusive worldwide licensing rights to the non-opoid investigational pain drug CNTX-0290 from Centrexion Therapeutics in a deal worth up to $997.5m (£789.24m).

Knopp reports positive preclinical data for neonatal epilepsy drug candidate

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today presented in vitro and in vivo data for the company’s lead molecule for the targeted treatment of KCNQ2-neonatal epileptic encephalopathy (KCNQ2-NEE) at the Antiepileptic Drug and Device Trials XV Conference in Miami, Florida.

Cyclica launches new multi-targeted drug design technology Ligand Design

Cyclica, a leading biotechnology company that commercialized Ligand Express announced its novel, first-in-class drug design technology, Ligand Design on stage at the Collision Conference in Toronto.